10/054,300

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13	OCT 19	E-mail format enhanced
NEWS 14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 22	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 23	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 24	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 25	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 26	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 27	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 28	DEC 18	CA/CAplus patent kind codes updated
NEWS 29	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 30	DEC 18	MEDLINE updated in preparation for 2007 reload

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

McIntosh

10/054,300

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:20:03 ON 18 DEC 2006

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:20:18 ON 18 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 DEC 2006  HIGHEST RN 915749-75-6
DICTIONARY FILE UPDATES:  15 DEC 2006  HIGHEST RN 915749-75-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10054300b.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 16:20:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        8 TO ITERATE

100.0% PROCESSED         8 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            8 TO      329
PROJECTED ANSWERS:               0 TO        0
```

McIntosh

10/054,300

L2 0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 16:20:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 197 TO ITERATE

100.0% PROCESSED 197 ITERATIONS 24 ANSWERS
SEARCH TIME: 00.00.01

L3 24 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'CAPLUS' ENTERED AT 16:20:53 ON 18 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 18 Dec 2006 VOL 145 ISS 26
FILE LAST UPDATED: 17 Dec 2006 (20061217/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 7 L3

=> d bib abs hitstr 1-7 l4

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:750731 CAPLUS
DN 137:295192
TI Preparation of bicyclonucleoside analogs and oligonucleotides containing them as nucleic acid reagents
IN Imanishi, Takeshi; Kohiyori, Satoshi
PA Sankyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 31 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002284793	A	20021003	JP 2002-6998	20020116
PRAI	JP 2001-9314	A	20010117		

OS MARPAT 137:295192
GI



I

Q=

II

AB Disclosed are nucleic acid reagents containing bicyclonucleoside analogs [I; R1 = H, HO-protecting group in DNA synthesis, PO3H2 optionally protected by a protecting group used in DNA synthesis, P(R4a)R4b (wherein R4a, R4b = OH, SH, or NH2 each optionally protected by a protecting group used in DNA synthesis, C1-6 alkoxy, C1-6 alkylthio, C1-7 cyanoalkoxy, C1-6 alkylamino); R2 = N3, NH2, NHR3 (wherein R3 = amino-protecting group in DNA synthesis, PO3H2 optionally protected by a protecting group used in DNA synthesis, P(R4a)R4b; wherein R4a, R4b = same as above); B = purin-9-yl or 2-oxo-1,2-dihydropyrimidin-1-yl optionally having ≥1 of any substituents selected from HO, SH, or NH2 each optionally protected by a protecting group used in DNA synthesis, C1-6 alkylamino, C1-6 alkyl, halo] or pharmacol. acceptable salts thereof. These bicyclonucleoside analogs have anti-AIDS activity and are useful as intermediates for oligonucleotide analogs possessing excellent antisense and anti-gene activity and stable in vivo. Also claimed are antisense or anti-gene drugs containing oligonucleotides containing ≥2 of 3'-amino-3'-deoxy-2'-O,4'-C-methylene bicyclonucleoside structure units represented by Q (wherein B = same as above) or pharmacol. acceptable salts thereof. Thus, to a solution of 22.1 mg 3'-O-(tert-butyldimethylsilyl)thymidine-5'-methylphosphonate (preparation given) in 0.3 mL CCl4 was added a solution of 10.0 mg 3'-amino-3'-deoxy-5'-(4,4'-dimethoxytrityl)-2'-O,4'-C-methylene-5-methyluridine (preparation given) and 0.05 mL Et3N in 0.2 mL MeCN and stirred at room temperature for 18 h to give a dinucleotide analog (II; DMTr = 4,4'-dimethoxytrityl; R = tert-butyldimethylsilyl) in 39% yield which (13.9 mg) was dissolved in 1 mL THF and stirred with 15 μL 1.0 M Bu4NF/THF at room temperature for 3 h to give 78% II (R = H). To a solution of 10.0 mg II (R = H) and 15.5 mg diisopropylammonium tetrazolide in 0.6 mL MeCN were added 0.2 mL THF and 39.8 mg 2-cyanoethyldiisopropylchlorophosphoramidite and stirred at room temperature for 25 h to give 31% II [R = P(OCH2CH2CN)N(i-Pr)2] which was used to prepare an oligonucleotide analog, 5'-TTTTTTTTTnT-3' (III; n = 3'-amino-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine residue) (4.3% yield) by the solid phase phosphoramidite method using a DNA synthesizer Gene Assembler Plus (Pharmacia Corp.). The oligonucleotide analog III exhibited the formability of a triple strand (Tm = 55°) with 2 natural-type oligonucleotides of 5'-GCTAAAAAGAAAGAGAGATCG-3' and 5'-CGATCTCTCTTTCTTTTTAGC-3', superior to that (Tm = 44) of a natural-type oligonucleotide of 5'-TTTTTmTTTmTmTmT-3' (m = 5-methyl-2'-deoxycytidine). III also exhibited the resistance against hydrolysis by 3'-exonuclease from Crotalus durissus (phosphodiesterase II) comparable to that of the known unnatural oligonucleotide, i.e. 5'-TTTTTTTTTn'T-3' (n' = 2'-O,4'-C-methylene-5-methyluridine).

IT 247025-17-8P, 3'-Azido-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of anti-AIDS bicyclonucleoside analogs and antisense and anti-gene oligonucleotide analogs containing them as nucleic acid reagents)

RN 247025-17-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-3-deoxy-4-C-(hydroxymethyl)-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 247025-18-9P, 3'-Amino-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anti-AIDS bicyclonucleoside analogs and antisense and anti-gene oligonucleotide analogs containing them as nucleic acid reagents)
RN 247025-18-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-amino-2,5-anhydro-3-deoxy-4-C-(hydroxymethyl)-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 247025-16-7P, 3'-Azido-5'-O-tert-butyldiphenylsilyl-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine 321882-28-4P, 3'-Azido-3'-deoxy-5'-O-(4,4'-dimethoxytrityl)-2'-O,4'-C-methylene-5-methyluridine 321882-29-5P, 3'-Amino-3'-deoxy-5'-O-(4,4'-dimethoxytrityl)-2'-O,4'-C-methylene-5-methyluridine 391259-82-8P 391259-84-0P 391259-85-1P 457659-26-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of anti-AIDS bicyclonucleoside analogs and antisense and anti-gene oligonucleotide analogs containing them as nucleic acid reagents)
RN 247025-16-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-3-deoxy-4-C-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

RN 321882-28-4 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-5-O-[bis(4-methoxyphenyl)phenylmethyl]-3-deoxy-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321882-29-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-amino-2,5-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-deoxy-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 391259-82-8 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-3'-deoxy-P,5-dimethyl-2'-O,4'-C-methyleneuridylyl-(3'→5')-3'-O-[(1,1-dimethylethyl)dimethylsilyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 391259-84-0 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-3'-deoxy-P,5-dimethyl-2'-O,4'-C-methyleneuridylyl-(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 391259-85-1 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-3'-deoxy-P,5-dimethyl-2'-O,4'-C-methyleneuridylyl-(3'→5')-, 3'-[2-cyanoethyl bis(1-methylethyl)phosphoramidite] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 457659-26-6 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-P-(2-cyanoethyl)-3'-deoxy-5-methyl-2'-O,4'-C-methyleneuridylyl-(3'→5')-3'-O-[(1,1-dimethylethyl)dimethylsilyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:691401 CAPLUS
DN 137:232861
TI Preparation of 3'-amino or 3'-amino-3'-deoxy-2'-O,4'-C-methylene nucleoside analogs and oligonucleotide analogs containing the nucleoside analogs and N3'-P5' bond as anti-AIDS drugs

McIntosh

10/054,300

IN Imanishi, Takeshi; Kohiyori, Satoshi
PA Sankyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 43 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002255990	A	20020911	JP 2001-352543	20011119
PRAI	JP 2000-354326	A	20001121		

OS MARPAT 137:232861
GI



AB Bicyclo nucleoside analogs having anti-AIDS activity, oligonucleotides possessing excellent antisense or anti-gene activity and in vivo stability, and intermediates thereof are provided. 3'-Amino or 3'-azido-3'-deoxy-2'-O,4'-C-methylene nucleoside analogs [I; R1 = H, hydroxy-protecting group in nucleic acid synthesis, P(O)(OH)2 optionally protected by a protecting group in nucleic acid synthesis, P(R4a)R4b (wherein R4a, R4b = OH, SH, or NH2 optionally protected by a protecting group in nucleic acid synthesis, C1-6 alkoxy, C1-6 alkylthio, C1-7 cyanoalkoxy, C1-6 alkylamino); R2 = N3, NH2, NHR3 (wherein R3 = amino-protecting group in nucleic acid synthesis), P(O)(OH)2 optionally protected by a protecting group in nucleic acid synthesis, P(R4a)R4b (wherein R4a, R4b = same as above); B = purin-9-yl or 2-oxo-1,2-dihydropyrimidin-1-yl optionally possessing ≥1 substituent group selected from HO, SH, or NH2 protected by a protecting group in nucleic acid synthesis, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkyl, and halo] and oligonucleotides containing 1 or ≥2 nucleoside residues represented by formula Q (B = same as above) or pharmacol. acceptable salts thereof are prepared Thus, 240 mg O,O'-bis(trimethylsilyl)thymine and 253 mg SnCl4 were added to a solution of 300 mg 3-azido-5-O-tert-butyldiphenylsilyl-3-deoxy-4-(p-toluenesulfonyloxymethyl)-1,2-di-O-acetyl-D-ribofuranose in 6 mL 1,2-dichloroethane and stirred r for 43 h to give 91% 2'-O-acetyl-3'-azido-5'-O-tert-butyldiphenylsilyl-3'-deoxy-4'-(p-toluenesulfonyloxymethyl)-5-methyluridine which were deprotected by treatment with K2CO3 in MeOH at room temperature for 4.5 h and with Bu4NF in THF at room temperature for 1 h to give 85% 3'-azido-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine (II). To a solution of 300 mg II in 6 mL pyridine was added 415 mg 4,4'-dimethoxytrityl chloride and 12.5 mg 4-dimethylaminopyridine and stirred at room temperature for 20.5 h to give 76% 3'-azido-3'-deoxy-2'-O,4'-C-methylene-5'-O-(4,4'-dimethoxytrityl)-5-methyluridine which (110 mg) was stirred with PPh3 in pyridine at room temperature for 3.5 h to give 97% 3'-amino-3'-deoxy-2'-O,4'-C-methylene-5'-O-(4,4'-dimethoxytrityl)-5-methyluridine (III). III (10.0 mg) was condensed with 22.1 mg 3'-O-(tert-butyldimethylsilyl)thymidine 5'-(Me phosphonate) in the presence of Et3N in CCl4/MeCN at room temperature for 18 h to give 39% dinucleotide analog (IV; R = tert-butyldimethylsilyl; DMTr = 4,4'-dimethoxytrityl) which was deprotected by treatment with Bu4NF in THF to give 78% IV (R = H). To a solution of 10.0 mg IV (R = H) and 15.5

mg diisopropylammonium tetrazolide in 0.6 mL MeCN and 0.2 mL THF was added 39.8 mg 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite and stirred at room temperature for 25 h to give dinucleotide analog phosphoramidite IV [R = P(CH2CH2CN)N(iPr)2] which was used to prepare oligonucleotide analogs, e.g. 5'-TTTTTmTnTmTmTmT-3' (V; m = 5-methyl-2'-deoxycytidine, n = 3'-amino-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine residue), by a Gene Assembler Plus DNA synthesizer (Pharmacia Corp.). V exhibited the formability of a triple strand (Tm = 55°) with 5'-GCTAAAAAGAAAGAGAGATCG-3' and 5'-CGATCTCTCTTTCTTTTTAGC-3' better than that (Tm = 44°) of natural oligonucleotide 5'-TTTTTmTTmTmTmT-3' (m = same as above).

IT 247025-17-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 3'-amino or 3'-amino-3'-deoxy-2'-O,4'-C-methylene nucleoside analogs and nuclease-resistant antisense oligonucleotide analogs containing them and N3'-P5' bonds as anti-AIDS drugs)

RN 247025-17-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-3-deoxy-4-C-(hydroxymethyl)-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 247025-18-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3'-amino or 3'-amino-3'-deoxy-2'-O,4'-C-methylene nucleoside analogs and nuclease-resistant antisense oligonucleotide analogs containing them and N3'-P5' bonds as anti-AIDS drugs)

RN 247025-18-9 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-amino-2,5-anhydro-3-deoxy-4-C-(hydroxymethyl)-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 247025-16-7P 321882-28-4P 321882-29-5P
391259-82-8P 391259-84-0P 391259-85-1P
457659-26-6P 457659-27-7P 457659-28-8P
457659-29-9P 457659-30-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3'-amino or 3'-amino-3'-deoxy-2'-O,4'-C-methylene nucleoside analogs and nuclease-resistant antisense oligonucleotide analogs containing

them and N3'-P5' bonds as anti-AIDS drugs)

RN 247025-16-7 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-3-deoxy-4-C-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321882-28-4 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-5-O-[bis(4-methoxyphenyl)phenylmethyl]-3-deoxy-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321882-29-5 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-amino-2,5-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-deoxy-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 391259-82-8 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-3'-deoxy-P,5-dimethyl-2'-O,4'-C-methyleneuridylyl-(3'→5')-3'-O-[(1,1-dimethylethyl)dimethylsilyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 391259-84-0 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-3'-deoxy-P,5-dimethyl-2'-O,4'-C-methyleneuridylyl-(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 391259-85-1 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-3'-deoxy-P,5-dimethyl-2'-O,4'-C-methyleneuridylyl-(3'→5')-, 3'-[2-cyanoethyl bis(1-methylethyl)phosphoramidite] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 457659-26-6 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-P-(2-cyanoethyl)-3'-deoxy-5-methyl-2'-O,4'-C-methyleneuridylyl-(3'→5')-3'-O-[(1,1-dimethylethyl)dimethylsilyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457659-27-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-amino-2,5-anhydro-3-deoxy-4-C-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457659-28-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-deoxy-4-C-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-3-[[(4-methoxyphenyl)diphenylmethyl]amino]-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457659-29-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-deoxy-4-C-(hydroxymethyl)-3-[[(4-methoxyphenyl)diphenylmethyl]amino]-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457659-30-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-4-C-[[[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]oxy]methyl]-3-deoxy-3-[[(4-methoxyphenyl)diphenylmethyl]amino]-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:517337 CAPLUS
DN 137:353253
TI Synthesis and antiviral evaluation of novel conformationally locked nucleosides and masked 5'-phosphate derivatives thereof
AU Bryld, Torsten; Sorensen, Marianne H.; Nielsen, Poul; Koch, Troels; Nielsen, Claus; Wengel, Jesper
CS Department of Chemistry, Nucleic Acid Center, University of Southern Denmark, Odense, DK-5230, Den.
SO Journal of the Chemical Society, Perkin Transactions 1 (2002), (14), 1655-1662
CODEN: JCSPCE; ISSN: 1472-7781
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 137:353253
AB As part of a program towards evaluating the potential of conformationally locked 3'-deoxy- and 3'-azido-3'-deoxy-nucleoside derivs. as prodrugs of potential 5'-O-triphosphorylated anti-HIV drugs, novel nucleoside derivs. with locked N-type (north-type, C3'-endo) furanose conformation were prepared using convergent synthetic strategies. In addition, masked 5'-monophosphate derivs. of these, and of a conformationally restricted 3'-azido-3'-deoxynucleoside with E-type (eastern-type, O4'-endo) furanose conformation, were prepared in order to potentially circumvent the first phosphorylation step. However, neither the free 5'-hydroxy derivs. nor the masked 5'-monophosphates showed anti-HIV activity in MT-4 cells.
IT 247025-17-8
RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(synthesis and antiviral activity of novel conformationally locked nucleosides and masked phosphate derivs. in order to evaluate the relationship between furanose conformation and anti-HIV activity)
RN 247025-17-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-3-deoxy-4-C-(hydroxymethyl)-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 474926-81-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and antiviral activity of novel conformationally locked nucleosides and masked phosphate derivs. in order to evaluate the relationship between furanose conformation and anti-HIV activity)
RN 474926-81-3 CAPLUS
CN 9H-Purin-6-amine, 9-[2,5-anhydro-3-azido-3-deoxy-4-C-(hydroxymethyl)-α-L-lyxofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 474927-20-3P 474927-26-9P 474927-28-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and antiviral activity of novel conformationally locked nucleosides and masked phosphate derivs. in order to evaluate the relationship between furanose conformation and anti-HIV activity)
RN 474927-20-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-3-deoxy-4-C-[[(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)oxy]methyl]-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474927-26-9 CAPLUS
CN L-Alanine, N-(3'-azido-3-deoxy-5-methyl-2'-O,4'-C-methylene-P-phenyl-5'-uridylyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474927-28-1 CAPLUS
CN L-Alanine, N-(3'-azido-3'-deoxy-2'-O,4'-C-methylene-P-phenyl-5'-adenylyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 474927-12-3P 474927-14-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and antiviral activity of novel conformationally locked nucleosides and masked phosphate derivs. in order to evaluate the relationship between furanose conformation and anti-HIV activity)
RN 474927-12-3 CAPLUS
CN 9H-Purin-6-amine, 9-[2,5-anhydro-3-azido-3-deoxy-4-C-[[(methylsulfonyl)oxy]methyl]-α-L-lyxofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

10/054,300

RN 474927-14-5 CAPLUS
CN 9H-Purin-6-amine, 9-[4-C-[(acetyloxy)methyl]-2,5-anhydro-3-azido-3-deoxy-α-L-lyxofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:768564 CAPLUS
DN 136:167631
TI 3'-Amino-2',4'-BNA: novel bridged nucleic acids having an N3'→P5' phosphoramidate linkage
AU Obika, Satoshi; Onoda, Mayumi; Morita, Koji; Andoh, Jun-ichi; Koizumi, Makoto; Imanishi, Takeshi
CS Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan
SO Chemical Communications (Cambridge, United Kingdom) (2001), (19), 1992-1993
CODEN: CHCOFS; ISSN: 1359-7345
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 136:167631
GI



I

AB Novel oligonucleotide analogs (I), containing a 3'-amino-2',4'-BNA unit, were successfully synthesized, and they showed superior duplex and triplex forming ability as well as BNA itself, along with remarkable enzymic stability.
IT 247025-17-8

McIntosh

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of bridged nucleic acids having an N3'→P5' phosphoramidate linkage and their effect on hybridization in DNA or RNA duplexes or triplexes)

RN 247025-17-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-3-deoxy-4-C-(hydroxymethyl)-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 321882-29-5P 391259-82-8P 391259-84-0P
391259-85-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bridged nucleic acids having an N3'→P5' phosphoramidate linkage and their effect on hybridization in DNA or RNA duplexes or triplexes)

RN 321882-29-5 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-amino-2,5-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-deoxy-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 391259-82-8 CAPLUS

CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-3'-deoxy-P,5-dimethyl-2'-O,4'-C-methyleneuridylyl-(3'→5')-3'-O-[(1,1-dimethylethyl)dimethylsilyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 391259-84-0 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-3'-deoxy-P,5-dimethyl-2'-O,4'-C-methyleneuridylyl-(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 391259-85-1 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-3'-deoxy-P,5-dimethyl-2'-O,4'-C-methyleneuridylyl-(3'→5')-, 3'-[2-cyanoethyl bis(1-methylethyl)phosphoramidite] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:78400 CAPLUS
DN 134:131768
TI Preparation of novel bicyclo nucleoside analogues as intermediates for oligonucleotide analogs both having anti-HIV activity
IN Imanishi, Takeshi; Kohiga, Satoshi
PA Sankyo Company, Ltd., Japan
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007455	A1	20010201	WO 2000-JP4902	20000721
	W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 2001089496	A	20010403	JP 2000-218496	20000719
	CA 2380205	A1	20010201	CA 2000-2380205	20000721
	AU 2000063135	A	20010213	AU 2000-63135	20000721
	AU 766656	B2	20031023		
	BR 2000012646	A	20020409	BR 2000-12646	20000721
	EP 1201678	A1	20020502	EP 2000-949882	20000721
	EP 1201678	B1	20040922		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	HU 200202812	A2	20021228	HU 2002-2812	20000721
	NZ 516653	A	20030926	NZ 2000-516653	20000721
	RU 2227143	C2	20040420	RU 2002-101317	20000721
	AT 277066	T	20041015	AT 2000-949882	20000721

	PT 1201678	T	20041130	PT 2000-949882	20000721
	ES 2226891	T3	20050401	ES 2000-949882	20000721
	ZA 2002000398	A	20030617	ZA 2002-398	20020116
	NO 2002000305	A	20020321	NO 2002-305	20020121
	US 2004143114	A1	20040722	US 2002-54300	20020122
	HK 1044776	A1	20050218	HK 2002-106305	20020827
PRAI	JP 1999-207170	A	19990722		
	WO 2000-JP4902	W	20000721		

OS MARPAT 134:131768

GI



I

10/054,300
my apf

AB Novel bicyclo nucleoside analogs having an anti-AIDS activity (no data), which are useful as intermediates for the preparation of oligonucleotide analogs having an excellent antisense or antigene activity and being stable in vivo, are claimed. Specifically, novel bicyclo nucleoside analogs represented by the structural formula (I) or pharmacol. acceptable salts thereof [wherein R1 is hydrogen, a hydroxyl-protecting group, PO3H2, or P(R4a)R4b (wherein R4a and R4b are (un)protected OH, SH, or NH2, C1-6 alkoxy, C1-6 alkylthio, C1-7 cyanoalkoxy, or C1-6 alkylamino); R2 is azido, optionally protected amino, or P(R4a)R4b (R4a and R4b are = same as above); and B is a purin-9-yl or 2-oxo-1,2-dihydropyrimidin-1-yl group which is optionally substituted with a member selected from the group consisting of halogeno, C1-C6 alkyl, hydroxyl, mercapto, amino, and so on] are prepared Thus, 300 mg 3-azido-5-(tert-butyldiphenylsilyl)-3-deoxy-4-(p-toluenesulfonyloxymethyl)-1,2-di-O-acetyl-D-ribofuranose was condensed with 240 mg O,O'-bis(trimethylsilyl)thymine in the presence of 253 mg SnCl4 in 1,2-dichloroethane at room temperature for 43 h to 91% give 2'-O-acetyl-3'-azido-5'-O-(tert-butyldiphenylsilyl)-3'-deoxy-4'-(p-toluenesulfonyloxymethyl)-5-methyluridine which (200 mg) was dissolved in 7 mL MeOH and stirred with 41 mg K2CO3 at room temperature for 4.5 h to give 100% 3'-azido-5'-O-(tert-butyldiphenylsilyl)-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine. The latter compound was stirred with Bu4NF in THF at room temperature for 1 h to give 85% 3'-azido-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine (II) which was hydrogenated over 10% Pd-C in THF to give 100% 3'-amino-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine. An oligonucleotide analog 5'-d(TTTTTTTTTT-n-T)-3' (T = 2'-deoxythymidine, n = 3'-amino-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine residue) was also prepared by the phosphoramidite using II as the intermediate.

IT 247025-16-7P 321882-28-4P 321882-29-5P
321882-30-8P 321882-31-9P 321882-32-0P
321882-33-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel bicyclo nucleoside analogs as intermediates for antisense or antigene oligonucleotide analogs both having anti-HIV activity for treatment of AIDS)

RN 247025-16-7 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-3-deoxy-4-C-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321882-28-4 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-5-O-[bis(4-methoxyphenyl)phenylmethyl]-3-deoxy-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321882-29-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-amino-2,5-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-deoxy-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321882-30-8 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-P(O)-(2-cyanoethyl)-P,3'-dideoxy-5-methyl-2'-O,4'-C-methyleneuridylyl-(3'→5')-3'-O-[(1,1-dimethylethyl)diphenylsilyl]- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 321882-31-9 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-P-deoxo-3'-deoxy-P(O),5-dimethyl-2'-O,4'-C-methyleneuridylyl-(3'→5')-3'-O-[(1,1-dimethylethyl)diphenylsilyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 321882-32-0 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-P-deoxo-3'-deoxy-P(O),5-dimethyl-2'-O,4'-C-methyleneuridylyl-(3'→5')- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



RN 321882-33-1 CAPLUS
CN Thymidine, 3'-amino-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-P-deoxo-3'-deoxy-P(O),5-dimethyl-2'-O,4'-C-methyleneuridylyl-(3'→5')-, 3'-[2-cyanoethyl bis(1-methylethyl)phosphoramidite] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 247025-17-8P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);

USES (Uses)
(preparation of novel bicyclo nucleoside analogs as intermediates for antisense or antigene oligonucleotide analogs both having anti-HIV activity for treatment of AIDS)

RN 247025-17-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-3-deoxy-4-C-(hydroxymethyl)-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 247025-18-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel bicyclo nucleoside analogs as intermediates for antisense or antigene oligonucleotide analogs both having anti-HIV activity for treatment of AIDS)

RN 247025-18-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-amino-2,5-anhydro-3-deoxy-4-C-(hydroxymethyl)-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:761652 CAPLUS
DN 134:101124
TI Synthesis and evaluation of anti-HIV-1 activity of 3'-azido-3'-deoxy-2'-O,4'-C-methylene-linked bicyclic thymine nucleosides
AU Olsen, Anne G.; Rajwanshi, Vivek K.; Nielsen, Claus; Wengel, Jesper
CS Department of Chemistry, Center for Synthetic Bioorganic Chemistry, University of Copenhagen, Copenhagen, DK-2100, Den.
SO Perkin 1 (2000), (21), 3610-3614
CODEN: PERKF9; ISSN: 1470-4358
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 134:101124
AB Two conformationally locked AZT analogs, each containing a 2'-O,4'-C-methylene-linked bicyclic furanose moiety, are synthesized via a 3'-azido-3'-deoxy-4'-C-hydroxymethyl nucleoside. The β-D-ribo-configured derivative is shown by NOE expts. to exist in a north-type (3E, C3'-endo) conformation and the α-L-xylo-configured derivative in a south-type (3E, C3'-exo) conformation. Both nucleosides were devoid of

anti-HIV activity in MT-4 cells.

IT 247025-17-8P 319919-16-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and evaluation of anti-HIV-1 activity of azidodeoxy-O,C-methylene-linked bicyclic thymine nucleosides)

RN 247025-17-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-3-deoxy-4-C-(hydroxymethyl)-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319919-16-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-3-deoxy-4-C-(hydroxymethyl)-β-D-arabinofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:570020 CAPLUS
DN 131:299638
TI Synthesis of a conformationally locked AZT analog, 3'-azido-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine
AU Obika, Satoshi; Andoh, Jun-Ichi; Sugimoto, Tomomi; Miyashita, Kazuyuki; Imanishi, Takeshi
CS Graduate School of Pharmaceutical Sciences, Osaka University, Suita, 565-0871, Japan
SO Tetrahedron Letters (1999), 40(35), 6465-6468
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
AB A bicyclic 3'-azido-3'-deoxythymidine (AZT) analog with a locked N-conformation, 3'-azido-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine (I), and its 3'-amino derivative, 3'-amino-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine, were successfully synthesized from D-glucose. The conformation of I was also discussed by means of 1H NMR measurements and a mol. modeling (PM3) study.
IT 247025-17-8P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP

(Preparation); RACT (Reactant or reagent)
(synthesis, conformation, and mol. modeling of a locked AZT analog azidodeoxymethylenemethyluridine)
RN 247025-17-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-3-deoxy-4-C-(hydroxymethyl)-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 247025-16-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis, conformation, and mol. modeling of a locked AZT analog azidodeoxymethylenemethyluridine)
RN 247025-16-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-3-azido-3-deoxy-4-C-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 247025-18-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis, conformation, and mol. modeling of a locked AZT analog azidodeoxymethylenemethyluridine)
RN 247025-18-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-amino-2,5-anhydro-3-deoxy-4-C-(hydroxymethyl)-α-L-lyxofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/054,300

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:20:03 ON 18 DEC 2006)

FILE 'REGISTRY' ENTERED AT 16:20:18 ON 18 DEC 2006
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 24 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:20:53 ON 18 DEC 2006
L4 7 S L3